936092-35-2

Upstream product

• 1780-31-0 2,6-dichloro-5-methylpyrimidine 
• 13726-14-2 4-chloro-m-anisidine 
• 16817-43-9 5-Bromo-2-chloroanisole 
• 14394-70-8 2-chloro-4-amino-5-methylpyrimidine 

Downstream Products

• 936092-45-4 4-{3-[4-(4-chloro-3-methoxy-phenylamino)-5-methyl-pyrimidin-2-ylamino]-benzyl}-piperazine-1-carboxylic acid tert-butyl ester 
• 1332719-16-0 C₂₈H₃₅ClN₆O₃ 
• 936092-62-5 4-{3-[4-(4-chloro-3-methoxy-phenylamino)-5-methyl-pyrimidin-2-ylamino]-phenyl}-piperazine-1-carboxylic acid tert butyl ester 
• 936092-44-3 4-{3-[4-(4-chloro-3-methoxy-phenylamino)-5-methyl-pyrimidin-2-ylamino]-benzyl}-piperazine-1-carboxylic acid tert butyl ester 
• 1332719-12-6 C₂₆H₃₂ClN₇O₃ 
• 1332719-14-8 C₂₉H₃₅ClN₆O₅ 

Relevant academic research and scientific papers

BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS

Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.

POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS

Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.

BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES

The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non receptor kinases.